FindTrial
Sign In

AZD1722

DRUG8 trials

Sponsors

Ardelyx

Conditions

Chronic Kidney DiseaseConstipation Predominant Irritable Bowel SyndromeHealthyHealthy VolunteerHealthy VolunteersHyperphosphatemiaType 2 Diabetes Mellitus

Phase 1

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study
CompletedNCT02063386
ArdelyxHealthy Volunteers
Start: 2014-04-30End: 2014-05-31Updated: 2015-09-22
To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers
CompletedNCT02140268
ArdelyxHealthy Volunteers
Start: 2014-05-31End: 2014-08-31Updated: 2015-09-22
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
CompletedNCT02176252
ArdelyxHealthy Volunteer
Start: 2013-07-31End: 2013-12-31Updated: 2014-06-27
A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
CompletedNCT02249936
ArdelyxHealthy
Start: 2013-02-28End: 2013-02-28Updated: 2014-09-26
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
CompletedNCT02346890
ArdelyxHealthy
Start: 2013-04-30End: 2013-04-30Updated: 2015-01-27

Phase 2

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
CompletedNCT01847092
ArdelyxChronic Kidney Disease, Type 2 Diabetes Mellitus
Start: 2013-05-31End: 2015-04-30Updated: 2020-05-27
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
CompletedNCT01923428
ArdelyxConstipation Predominant Irritable Bowel Syndrome
Start: 2013-08-31End: 2014-10-31Updated: 2020-04-08
Dose Finding Study to Treat High Phosphate Levels in the Blood.
CompletedNCT02081534
ArdelyxHyperphosphatemia
Start: 2014-03-31End: 2014-11-30Updated: 2020-09-14

Related Papers

Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis.
2026-01-24
Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation
Digestive Diseases2024-12-194 citations
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
The American Journal of Gastroenterology2024-01-3111 citations
S232 Improvement in Bloating and Overall Complete Spontaneous Bowel Movement Response With Tenapanor Treatment: A Post Hoc Analysis of the IBS-C Clinical Studies
The American Journal of Gastroenterology2023-10-01
S239 Tenapanor Can Improve Abdominal Symptoms Independent of Changes in Bowel Movement Frequency in Adult Patients with IBS-C
The American Journal of Gastroenterology2023-10-01
S171 Tenapanor Treatment Success for IBS-C Symptoms Increases with Duration of Therapy
The American Journal of Gastroenterology2023-10-01
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
2019-02-0127 citations
Efficacy and Safety of Tenapanor in Patients With Constipation Predominant Irritable Bowel Syndrome: A 12-week, Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial
The American Journal of Gastroenterology2017-10-014 citations
Tenapanor administration and the activity of the H<sup>+</sup> -coupled transporter PepT1 in healthy volunteers.
2017-05-318 citations
Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
Clinical Pharmacology in Drug Development2017-03-1613 citations
The Effect of Tenapanor on Global Endpoints in Patients with Constipation Predominant Irritable Bowel Syndrome: Results from a 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial
The American Journal of Gastroenterology2016-09-29
Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders
Clinical Pharmacology in Drug Development2016-09-2218 citations
A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
2016-07-0139 citations
Tenapanorʼs Sustained Response in Patients With Constipation Predominant Irritable Bowel Syndrome: Post-hoc Analysis From a 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial
The American Journal of Gastroenterology2015-10-01